265108-36-9

Basic information

• Product Name: Cyclohexanecarboxaldehyde, 4,4-difluoro- (9CI)
• Synonyms: Cyclohexanecarboxaldehyde, 4,4-difluoro- (9CI);4,4-Difluoro Cyclohexanecarboxaldehyde;4,4-Difluoro-cyclohexanecarbaldehyde;4,4-difluorocyclohexane-1-carbaldehyde;Cyclohexanecarboxaldehyde, 4,4-difluoro-
• CAS NO: 265108-36-9
• Molecular Formula: C₇H₁₀F₂O
• Molecular Weight: 148.1505064
• Product Categories: HALIDE;ALDEHYDE
• Mol File: 265108-36-9.mol
• Article Data: 21

Chemical Properties

• Boiling Point: 165 °C at 760 mmHg
• Flash Point: 59 °C
• Appearance: /
• Density: 1.1 g/cm³
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: Cyclohexanecarboxaldehyde, 4,4-difluoro- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclohexanecarboxaldehyde, 4,4-difluoro- (9CI)(265108-36-9)
• EPA Substance Registry System: Cyclohexanecarboxaldehyde, 4,4-difluoro- (9CI)(265108-36-9)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 265108-36-9(Hazardous Substances Data)

Usage

Description

Cyclohexanecarboxaldehyde, 4,4-difluoro(9CI) is an organic compound characterized by the presence of a cyclohexane ring with a formyl group (-CHO) and two fluorine atoms attached to the 4th carbon. This unique structure endows it with specific chemical properties that make it suitable for various applications in different industries.

Uses

Used in Pharmaceutical Industry:
Cyclohexanecarboxaldehyde, 4,4-difluoro(9CI) is used as a key intermediate in the synthesis of heteroaryl acid derivatives. These derivatives are essential in the development of novel pharmaceutical compounds, particularly those targeting oxalate-related diseases. The unique structural features of this compound allow for the creation of new molecules with potential therapeutic benefits.
Used in Chemical Synthesis:
In the field of chemical synthesis, Cyclohexanecarboxaldehyde, 4,4-difluoro(9CI) serves as a valuable building block for the development of various organic compounds. Its fluorinated nature and reactive aldehyde group make it a versatile starting material for the synthesis of a wide range of molecules with diverse applications, including pharmaceuticals, agrochemicals, and specialty chemicals.
Used in Research and Development:
Due to its unique structure and reactivity, Cyclohexanecarboxaldehyde, 4,4-difluoro(9CI) is also utilized in research and development laboratories. It can be employed as a model compound to study the effects of fluorination on the properties and reactivity of cyclohexane derivatives. Additionally, it can be used to explore new reaction pathways and develop innovative synthetic methods for the preparation of complex organic molecules.

Upstream product

• 394-02-5 5-fluoro-2-nitrobenzoyl chloride 
• 917383-03-0 4,4-difluoro-N-methoxy-N-methylcyclohexane-1-carboxamide 
• 178312-48-6 (4,4-difluorocyclohexyl)methanol 
• 178312-47-5 ethyl 4,4-difluorocyclohexane-1-carboxylate 
• 121629-14-9 methyl 4,4-difluorocyclohexane-1-carboxylate 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 3618-04-0 4-hydroxycyclohexyl carboxylic acid ethyl ester 
• 122665-97-8 4,4-difluorocyclohexanecarboxylic acid 

Downstream Products

• 1265885-42-4 N-benzyl-2-[2-(4-chloro-phenyl)-5,6-difluoro-benzoimidazol-1-yl]-2-(4,4-difluoro-cyclohexyl)-acetamide 
• 1156469-52-1 C₉H₁₄F₂O 
• 1333426-95-1 C₁₆H₂₉F₂NOSSi 
• 1333426-96-2 C₁₃H₂₁F₂NOS 
• 1427058-51-2 tert-butyl N-{1-[(4,4-difluorocyclohexyl)methyl]piperidin-4-yl}carbamate 
• 1430091-59-0 methyl 3-(4,4-difluorocyclohexyl)prop-2-enoate 
• 1430091-62-5 methyl 3-(4,4-difluorocyclohexyl)-4-nitrobutanoate 
• 1430091-65-8 methyl (3R)-3-(4,4-difluorocyclohexyl)-4-nitrobutanoate 
• 1430091-66-9 methyl (3S)-3-(4,4-difluorocyclohexyl)-4-nitrobutanoate 
• 1430091-67-0 4-(4,4-difluorocyclohexyl)pyrrolidin-2-one 
• 1430091-75-0 3-(4,4-difluorocyclohexyl)pyrrolidine 
• 1354495-10-5 (-)-(5S)-2-[1-(5-cyclopropylpyrimidin-2-yl)piperidin-4-yl]-4-(4,4-difluorocyclohexyl)-3-{(S)-fluoro[4-(trifluoromethyl)phenyl]methyl}-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-5-ol 
• 1354495-76-3 4-(4,4-difluorocyclohexyl)-3-{fluoro[4-(trifluoromethyl)phenyl]methyl}-2-[1-(5-formylpyrimidin-2-yl)piperidin-4-yl]-5-[(4-methoxybenzyl)oxy]-7,7-dimethyl-5,6,7,8-tetrahydroquinoline 
• 1354495-13-8 (5S)-4-(4,4-difluorocyclohexyl)-3-{(S)-fluoro[4-(trifluoromethyl)phenyl]methyl}-2-[1-[5-(hydroxymethyl)pyrimidin-2-yl]piperidin-4-yl]-5-[(4-methoxybenzyl)oxy]-7,7-dimethyl-5,6,7,8-tetrahydroquinoline 

Relevant articles and documents

Structure-Guided Design of Potent Inhibitors of SARS-CoV-2 3CL Protease: Structural, Biochemical, and Cell-Based Studies

The COVID-19 pandemic is having a major impact on public health worldwide, and there is an urgent need for the creation of an armamentarium of effective therapeutics, including vaccines, biologics, and small-molecule therapeutics, to combat SARS-CoV-2 and emerging variants. Inspection of the virus life cycle reveals multiple viral- and host-based choke points that can be exploited to combat the virus. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for therapeutic intervention, and the design of inhibitors of the protease may lead to the emergence of effective SARS-CoV-2-specific antivirals. We describe herein the results of our studies related to the application of X-ray crystallography, the Thorpe–Ingold effect, deuteration, and stereochemistry in the design of highly potent and nontoxic inhibitors of SARS-CoV-2 3CLpro.

COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES

Disclosed herein are compounds and compositions for modulating glycolate oxidase, useful for treating oxalate-related diseases, such as hyperoxaluria, where modulating glycolate oxidase is expected to be therapeutic to a patent in need thereof. Methods of modulating glycolate oxidase activity in a human or animal subject are also provided.

CARBOXAMIDE AND SULFONAMIDE DERIVATIVES USEFUL AS TEAD MODULATORS

The invention is concerned with the compounds of formula (I) and formula (II): and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of using the compounds of formula (I) and formula (II) as well as pharmaceutical compositions containing such compounds. The compounds are useful in treating diseases and conditions mediated by TEAD, such as cancer.